# Adoptive Cellular Immunotherapy Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma

> **NCT00439465** · PHASE2 · COMPLETED · sponsor: **Dartmouth-Hitchcock Medical Center** · enrollment: 23 (actual)

## Conditions studied

- Myeloma
- Transplant-eligible Patients

## Interventions

- **BIOLOGICAL:** Ex-vivo expanded effector cells

## Key facts

- **NCT ID:** NCT00439465
- **Lead sponsor:** Dartmouth-Hitchcock Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2012-10-15
- **Final completion:** 2012-11-30
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2019-03-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00439465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00439465, "Adoptive Cellular Immunotherapy Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00439465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*